Human ADAM28 ELISA Kit (V2LY-0626-LY4496)

Zhong, Y., Lin, H., Li, Q., Liu, C., & Shen, J. (2021). CircRNA_100565 contributes to cisplatin resistance of NSCLC cells by regulating proliferation, apoptosis and autophagy via miR-337-3p/ADAM28 axis. Cancer Biomarkers, 30(2), 261-273.

Zha, Z., Jia, F., Hu, P., Mai, E., & Lei, T. (2020). MicroRNA‑574‑3p inhibits the malignant behavior of liver cancer cells by targeting ADAM28. Oncology letters, 20(3), 3015-3023.

Hubeau, C., Rocks, N., & Cataldo, D. (2020). ADAM28: Another ambivalent protease in cancer. Cancer Letters, 494, 18-26.

Li, L. X., Lam, I. H., Liang, F. F., Yi, S. P., Ye, L. F., Wang, J. T., ... & Xu, M. (2019). MiR-198 affects the proliferation and apoptosis of colorectal cancer through regulation of ADAM28/JAK-STAT signaling pathway. Eur Rev Med Pharmacol Sci, 23(4), 1487-1493.

Wei, L., Wen, J. Y., Chen, J., Ma, X. K., Wu, D. H., Chen, Z. H., & Huang, J. L. (2019). Oncogenic ADAM28 induces gemcitabine resistance and predicts a poor prognosis in pancreatic cancer. World journal of gastroenterology, 25(37), 5590.

Mochizuki, S., Shimoda, M., Abe, H., Miyamae, Y., Kuramoto, J., Aramaki-Hattori, N., ... & Okada, Y. (2018). Selective inhibition of ADAM28 suppresses lung carcinoma cell growth and metastasis. Molecular cancer therapeutics, 17(11), 2427-2438.

Gérard, C., Hubeau, C., Carnet, O., Bellefroid, M., Sounni, N. E., Blacher, S., ... & Rocks, N. (2018). Microenvironment-derived ADAM28 prevents cancer dissemination. Oncotarget, 9(98), 37185.

Herat, L., Rudnicka, C., Okada, Y., Mochizuki, S., Schlaich, M., & Matthews, V. (2017). The metalloproteinase ADAM28 promotes metabolic dysfunction in mice. International journal of molecular sciences, 18(4), 884.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols